Search Results 71-80 of 24189 for B cell lymphomas
Clinical Trials · MC230813 A Study of Golcadomide with Rituximab prior to CAR-T with Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL).
Giving rituximab together with romidepsin and lenalidomide may be a better treatment for B-cell non-Hodgkin lymphoma. Participation eligibility. Participant ...
The purpose of this study is to evaluate the safety and tolerability of STP938 as a single agent in adult subjects with R/R B-cell and T-cell lymphomas.
A Study Evaluating the Effectiveness and Safety of Axicabtagene Ciloleucel in Subjects with High-Risk Large B-Cell Lymphoma · More about research at Mayo Clinic.
... B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL). Participation eligibility. Participant eligibility includes ...
Monoclonal B-cell lymphocytosis (MBL) causes an increased number of a type of lymphocyte, called B lymphocytes, in the blood. ... B-cell lymphoma. This is ...
T-cell/histiocyte-rich large B cell lymphoma. Large B-cell lymphoma with ... FDG-nonavid lymphomas: Measurable disease with CT (or MRI) scan with ...
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Relapse in Aggressive B-cell Non-Hodgkin Lymphomas · Overview · Participation eligibility.
Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus RCHOP in Participants with Previously Untreated High-risk Large B-cell Lymphoma.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!